IL3RA and CD4+/CD56+ hematodermic neoplasm: Lane et al. reported the preliminary results of a phase Ib study exploring the safety and efficacy of combining tagraxofusp with azacitidine, or azacitidine and venetoclax, in CD123-positive AML, MDS, or BPDCN patients; in this report, three relapsing/refractory BPDCN patients were included and were treated with the triplet tagraxofusp, azacitidine, and venetoclax: two of these patients responded to this treatment, achieving a CR or CRi response and were bridged to allo-stem cell transplantation [53] (Table 1).